KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for BeOne Medicines (ONC) over the last 11 years, with Q3 2025 value amounting to $2.0 billion.

  • BeOne Medicines' Non-Current Assets rose 255.25% to $2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year increase of 255.25%. This contributed to the annual value of $1.9 billion for FY2024, which is 2044.22% up from last year.
  • As of Q3 2025, BeOne Medicines' Non-Current Assets stood at $2.0 billion, which was up 255.25% from $2.0 billion recorded in Q2 2025.
  • BeOne Medicines' Non-Current Assets' 5-year high stood at $2.0 billion during Q2 2025, with a 5-year trough of $680.0 million in Q1 2021.
  • Its 5-year average for Non-Current Assets is $1.4 billion, with a median of $1.3 billion in 2023.
  • In the last 5 years, BeOne Medicines' Non-Current Assets soared by 5782.49% in 2022 and then soared by 255.25% in 2025.
  • BeOne Medicines' Non-Current Assets (Quarter) stood at $921.6 million in 2021, then increased by 27.19% to $1.2 billion in 2022, then skyrocketed by 36.65% to $1.6 billion in 2023, then increased by 20.44% to $1.9 billion in 2024, then rose by 2.01% to $2.0 billion in 2025.
  • Its Non-Current Assets was $2.0 billion in Q3 2025, compared to $2.0 billion in Q2 2025 and $1.9 billion in Q1 2025.